The effects of serum separated from patients with sepsis on the expression of CXCR7 in mesenchymal stem cells (MSCs)
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 Esfand 2025
,
Page 1-10
https://doi.org/10.22037/aab.v16i1.49304
Abstract
Introduction: Sepsis is a leading cause of death in intensive care unit (ICU) patients. This condition, in its advanced stage, leads to dysfunction of vital organs, resulting in the death of patients. Mesenchymal stem cells (MSCs) aid tissue regeneration by migrating to damaged areas, a process regulated by the CXCR7 gene. This study investigates the effect of serum from septic patients on the CXCR7 expression in MSCs.
Materials and Methods: The blood serum of 20 patients with sepsis was collected. The hUCB-MSCs were cultured under laboratory conditions (in vitro). Four groups of cells were treated with serum from patients and a control group was treated with serum from healthy volunteers. After 24 and 48 hours, the cells were trypsinized and RNA was extracted. cDNA was synthesized using a reverse transcription reaction and a specific kit. The expression level of this gene was determined using qRT-PCR.
Results: The results indicated that the expression of the CXCR7 gene in hUCB-MSCs treated with serum from sepsis patients significantly increased after 24 hours compared to the control group. Additionally, the expression level of this gene in the 48-hour treatment group showed a significant increase compared to the control groups and the 24-hour treatment group.
Conclusion: Exposure of hUCB-MSCs to septic patient serum led to a significant upregulation of CXCR7 compared with healthy serum (mean relative 2^−ΔΔCt fold-change: 24 h = 3.3-fold; 48 h = 19.3-fold; P < 0.01). These results are preliminary and warrant further functional and in vivo studies to confirm the biological and therapeutic implications of CXCR7 modulation in MSCs.
- Sepsis
- CXCR7 gene
- stem cells
- mesenchymal stem cells (MSCs)
- umbilical cord
- human
How to Cite
References
[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-10. [DOI: 10.1001/jama.2016.0287] [PMID]
[2] Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. [DOI: 10.1186/cc8872] [PMID]
[3] Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019;2019:4236973. [DOI: 10.1155/2019/4236973] [PMID]
[4] Lalu MM, McIntyre L, Pugliese C, Stewart DJ. Safety of cell therapy with mesenchymal stromal cells (MSCs): a systematic review. Am J Respir Crit Care Med. 2010;181:A6043. [DOI: 10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A6043] [PMID]
[5] McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, et al. Cellular immunotherapy for septic shock: a phase I clinical trial. Am J Respir Crit Care Med. 2018;197(3):337-47. [DOI: 10.1164/rccm.201705-1006OC] [PMID]
[6] Sun XY, Ding XF, Liang HY, Zhang XJ, Liu SH, Bing-Han, et al. Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies. Stem Cell Res Ther. 2020;11(1):214. [DOI: 10.1186/s13287-020-01730-7] [PMID]
[7] Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7(2):368-79. [DOI: 10.4252/wjsc.v7.i2.368] [PMID]
[8] Vagima Y, Lapid K, Kollet O, Goichberg P, Alon R, Lapidot T. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods Mol Biol. 2011;750:277-89. [DOI: 10.1007/978-1-61779-145-1_19] [PMID]
[9] Ling L, Hou J, Liu D, Tang D, Zhang Y, Zeng Q, et al. Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). Stem Cell Res Ther. 2022;13(1):79. [DOI: 10.1186/s13287-022-02759-6] [PMID]
[10] Balabanian K, Lagane B, Infantino S, Chow KYC, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem. 2005;280(42):35760-6. [DOI: 10.1074/jbc.M508234200] [PMID]
[11] Heinrich EL, Lee W, Lu J, Lowy AM, Kim J. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med. 2012;10:68. [DOI: 10.1186/1479-5876-10-68] [PMID]
[12] Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, et al. β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci U S A. 2010;107(2):628-32. [DOI: 10.1073/pnas.0912852107] [PMID]
[13] Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013;24(1):41-9. [DOI: 10.1016/j.cytogfr.2012.08.007] [PMID]
[14] Wei ST, Huang YC, Chiang JY, Lin CC, Lin YJ, Shyu WC, et al. Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation. Stem Cell Res Ther. 2021;12(1):314. [DOI: 10.1186/s13287-021-02402-w] [PMID]
[15] Xu J, Miao S, Wu T, Hu C, Huang D, Zhang X. CXCR7 promotes pulmonary vascular remodeling via targeting p38/MMP2 pathway in pulmonary arterial hypertension. J Thorac Dis. 2024;16(4):2460-71. [DOI: 10.21037/jtd-24-331] [PMID]
[16] Zhang S, Yue J, Ge Z, Xie Y, Zhang M, Jiang L. Activation of CXCR7 alleviates cardiac insufficiency after myocardial infarction by promoting angiogenesis and reducing apoptosis. Biomed Pharmacother. 2020;127:110168. [DOI: 10.1016/j.biopha.2020.110168] [PMID]
[17] Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, et al. Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction: implications for cardiovascular drug discovery. Circulation. 2017;135(13):1253-64. [DOI: 10.1161/CIRCULATIONAHA.116.023027] [PMID]
[18] Liu S, Jia X, Li C, Han X, Yan W, Xing Y. CXCR7 silencing attenuates cell adaptive response to stromal cell derived factor 1α after hypoxia. PLoS One. 2013;8(1):e55290. [DOI: 10.1371/journal.pone.0055290] [PMID]
[19] Pouzol L, Sassi A, Baumlin N, Tunis M, Strasser DS, Lehembre F, et al. CXCR7 antagonism reduces acute lung injury pathogenesis. Front Pharmacol. 2021;12:748740. [DOI: 10.3389/fphar.2021.748740] [PMID]
[20] Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12. [DOI: 10.1186/1478-811X-9-12] [PMID]
[21] Jones GE, editor. Human cell culture protocols. Totowa (NJ): Humana Press; 1996. [DOI: 10.1385/089603335X]
[22] Lukeš J. 1, 2, 4 1 Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic; email:[email protected],[email protected] 2 Faculty of Science, University of South Bohemia, 37005 České Budějovice, Czech Republic 3 Institute of Microbiology. Czech Academy of Sciences.;379(81):129-44. [LINK]
[23] Otu A, Elston J, Nsutebu E. Sepsis in Africa: practical steps to stem the tide. Pan Afr Med J. 2015;21:323. [DOI: 10.11604/pamj.2015.21.323.6462] [PMID]
[24] Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW, et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020;15(1):41-6. [DOI: 10.1038/s41565-019-0600-1] [PMID]
[25] Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204-18. [DOI: 10.18632/oncotarget.23208] [PMID]
[26] Tang X, Li X, Li Z, Liu Y, Yao L, Song S, et al. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells. Tumour Biol. 2016;37(10):13425-33. [DOI: 10.1007/s13277-016-5180-1] [PMID]
[27] Gonzalez MA, Ochoa CD. Multiorgan system failure in sepsis. In: Ortiz-Ruiz G, Dueñas-Castell C, editors. Sepsis. 3rd ed. New York: Springer; 2018. p. 67-71. [DOI: 10.1007/978-1-4939-7334-7_6]
[28] Warttig S, Alderson P, Evans DJW, Lewis SR, Kourbeti IS, Smith AF. Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients. Cochrane Database Syst Rev. 2018;6(6):CD012404. [DOI: 10.1002/14651858.CD012404.pub2] [PMID]
[29] Galstyan G, Makarova P, Parovichnikova E, Kuzmina L, Troitskaya V, Gemdzhian E, et al. The results of the single center pilot randomized Russian clinical trial of mesenchymal stromal cells in severe neutropenic patients with septic shock (RUMCESS). Int J Blood Res Disord. 2018;5:033. [DOI: 10.23937/2469-5696/1410033]
[30] Jain K, Mohan KV, Roy G, Sinha P, Jayaraman V, Kiran, et al. Reconditioned monocytes are immunomodulatory and regulate inflammatory environment in sepsis. Sci Rep. 2023;13(1):14977. [DOI: 10.1038/s41598-023-42237-4] [PMID]
- Abstract Viewed: 214 times
- PDF Downloaded: 16 times